The greater number of medical conditions that adipose-derived stem and regenerative cells can be shown to improve, the broader the potential for recurring revenue. Our significant investment of time and resources over the past decade has been dedicated to optimizing the Celution® System hardware and consumables, so that today, only incremental investments are needed to expand the number of applications of its cell output.
Cytori recently completed two safety & feasibility clinical trials in Europe for cardiovascular disease, the most advanced application in our pipeline. Six month data from both trials, for heart attack and chronic ischemia, will be analyzed in 2010. Cardiovascular disease is one of the largest healthcare market opportunities.>>Learn More
In addition to our efforts in a number of areas, independent investigators at academic universities around the globe are exploring additional applications for the Celution® technology including cardiovascular disease, urinary incontinence, wound healing, liver and kidney failure, pancreatitis and spinal disc disease.